Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Autopsy Analyses in Neurological Drug Development-Opening the Black Box.

Bishop KM.

JAMA Neurol. 2019 Aug 5. doi: 10.1001/jamaneurol.2019.2265. [Epub ahead of print] No abstract available.

PMID:
31380941
2.

Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy.

Montes J, Dunaway Young S, Mazzone ES, Pasternak A, Glanzman AM, Finkel RS, Darras BT, Muntoni F, Mercuri E, De Vivo DC, Bishop KM, Schneider E, Bennett CF, Foster R, Farwell W; CS2 and CS12 Study Groups.

Muscle Nerve. 2019 Jul 12. doi: 10.1002/mus.26633. [Epub ahead of print]

PMID:
31298747
3.

Local Drug Delivery for the Treatment of Neurotology Disorders.

Piu F, Bishop KM.

Front Cell Neurosci. 2019 Jun 3;13:238. doi: 10.3389/fncel.2019.00238. eCollection 2019. Review.

4.

Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies.

Darras BT, Chiriboga CA, Iannaccone ST, Swoboda KJ, Montes J, Mignon L, Xia S, Bennett CF, Bishop KM, Shefner JM, Green AM, Sun P, Bhan I, Gheuens S, Schneider E, Farwell W, De Vivo DC; ISIS-396443-CS2/ISIS-396443-CS12 Study Groups.

Neurology. 2019 May 21;92(21):e2492-e2506. doi: 10.1212/WNL.0000000000007527. Epub 2019 Apr 24.

5.

Evaluator Training and Reliability for SMA Global Nusinersen Trials1.

Glanzman AM, Mazzone ES, Young SD, Gee R, Rose K, Mayhew A, Nelson L, Yun C, Alexander K, Darras BT, Zolkipli-Cunningham Z, Tennekoon G, Day JW, Finkel RS, Mercuri E, De Vivo DC, Baldwin R, Bishop KM, Montes J.

J Neuromuscul Dis. 2018;5(2):159-166. doi: 10.3233/JND-180301.

6.

Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.

Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, Iannaccone ST, Kirschner J, Kuntz NL, Saito K, Shieh PB, Tulinius M, Mazzone ES, Montes J, Bishop KM, Yang Q, Foster R, Gheuens S, Bennett CF, Farwell W, Schneider E, De Vivo DC, Finkel RS; CHERISH Study Group.

N Engl J Med. 2018 Feb 15;378(7):625-635. doi: 10.1056/NEJMoa1710504.

7.

Motor milestone assessment of infants with spinal muscular atrophy using the hammersmith infant neurological Exam-Part 2: Experience from a nusinersen clinical study.

Bishop KM, Montes J, Finkel RS.

Muscle Nerve. 2018 Jan;57(1):142-146. doi: 10.1002/mus.25705. Epub 2017 Jun 14.

PMID:
28556387
8.

Progress and promise of antisense oligonucleotide therapeutics for central nervous system diseases.

Bishop KM.

Neuropharmacology. 2017 Jul 1;120:56-62. doi: 10.1016/j.neuropharm.2016.12.015. Epub 2016 Dec 18. Review.

PMID:
27998711
9.

Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.

Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, Yamashita M, Rigo F, Hung G, Schneider E, Norris DA, Xia S, Bennett CF, Bishop KM.

Lancet. 2016 Dec 17;388(10063):3017-3026. doi: 10.1016/S0140-6736(16)31408-8. Epub 2016 Dec 7.

PMID:
27939059
10.

Spinal Muscular Atrophy Type I: Is It Ethical to Standardize Supportive Care Intervention in Clinical Trials?

Finkel RS, Bishop KM, Nelson RM.

J Child Neurol. 2017 Feb;32(2):155-160. doi: 10.1177/0883073816671236. Epub 2016 Oct 22.

11.

Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy.

Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Montes J, De Vivo DC, Norris DA, Bennett CF, Bishop KM.

Neurology. 2016 Mar 8;86(10):890-7. doi: 10.1212/WNL.0000000000002445. Epub 2016 Feb 10.

12.

Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience.

Haché M, Swoboda KJ, Sethna N, Farrow-Gillespie A, Khandji A, Xia S, Bishop KM.

J Child Neurol. 2016 Jun;31(7):899-906. doi: 10.1177/0883073815627882. Epub 2016 Jan 27.

13.

Guidelines for dementia-related health advocacy for adults with intellectual disability and dementia: National Task Group on Intellectual Disabilities and Dementia Practices.

Bishop KM, Hogan M, Janicki MP, Keller SM, Lucchino R, Mughal DT, Perkins EA, Singh BK, Service K, Wolfson S; Health Planning Work Group of National Task Group on Intellectual Disabilities and Dementia Practices.

Intellect Dev Disabil. 2015 Feb;53(1):2-29. doi: 10.1352/1934-9556-53.1.2.

PMID:
25633379
14.

An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study.

Miller TM, Pestronk A, David W, Rothstein J, Simpson E, Appel SH, Andres PL, Mahoney K, Allred P, Alexander K, Ostrow LW, Schoenfeld D, Macklin EA, Norris DA, Manousakis G, Crisp M, Smith R, Bennett CF, Bishop KM, Cudkowicz ME.

Lancet Neurol. 2013 May;12(5):435-42. doi: 10.1016/S1474-4422(13)70061-9. Epub 2013 Mar 29. Erratum in: Lancet Neurol. 2013 May;12(5):423.

15.

Healthy aging for older adults with intellectual and development disabilities.

Bishop KM, Robinson LM, VanLare S.

J Psychosoc Nurs Ment Health Serv. 2013 Jan;51(1):15-8.

PMID:
23413456
16.

Growing health disparities for persons who are aging with intellectual and developmental disabilities: the social work linchpin.

Robinson LM, Dauenhauer J, Bishop KM, Baxter J.

J Gerontol Soc Work. 2012;55(2):175-90. doi: 10.1080/01634372.2011.644030.

PMID:
22324333
17.

Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically active neurotrophic factor proteins for neurodegenerative diseases.

Herzog CD, Bishop KM, Brown L, Wilson A, Kordower JH, Bartus RT.

Drug Deliv Transl Res. 2011 Oct;1(5):361-82. doi: 10.1007/s13346-011-0037-z.

PMID:
25788422
18.

Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease.

Herzog CD, Brown L, Gammon D, Kruegel B, Lin R, Wilson A, Bolton A, Printz M, Gasmi M, Bishop KM, Kordower JH, Bartus RT.

Neurosurgery. 2009 Apr;64(4):602-12; discussion 612-3. doi: 10.1227/01.NEU.0000340682.06068.01.

PMID:
19349823
19.

Intraspinal cord delivery of IGF-I mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS.

Franz CK, Federici T, Yang J, Backus C, Oh SS, Teng Q, Carlton E, Bishop KM, Gasmi M, Bartus RT, Feldman EL, Boulis NM.

Neurobiol Dis. 2009 Mar;33(3):473-81. doi: 10.1016/j.nbd.2008.12.003. Epub 2008 Dec 24.

PMID:
19135533
20.

Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons.

Bishop KM, Hofer EK, Mehta A, Ramirez A, Sun L, Tuszynski M, Bartus RT.

Exp Neurol. 2008 Jun;211(2):574-84. doi: 10.1016/j.expneurol.2008.03.004. Epub 2008 Mar 19.

21.

Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS.

Lepore AC, Haenggeli C, Gasmi M, Bishop KM, Bartus RT, Maragakis NJ, Rothstein JD.

Brain Res. 2007 Dec 14;1185:256-65. Epub 2007 Sep 22.

22.

AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease.

Gasmi M, Brandon EP, Herzog CD, Wilson A, Bishop KM, Hofer EK, Cunningham JJ, Printz MA, Kordower JH, Bartus RT.

Neurobiol Dis. 2007 Jul;27(1):67-76. Epub 2007 Apr 19.

PMID:
17532642
23.

Potential target genes of EMX2 include Odz/Ten-M and other gene families with implications for cortical patterning.

Li H, Bishop KM, O'Leary DD.

Mol Cell Neurosci. 2006 Oct;33(2):136-49. Epub 2006 Aug 17.

PMID:
16919471
24.

Randomized phase II study of GM-CSF to reduce mucositis caused by accelerated radiotherapy of laryngeal cancer.

McAleese JJ, Bishop KM, A'Hern R, Henk JM.

Br J Radiol. 2006 Jul;79(943):608-13.

PMID:
16823067
25.

Recombinant inbreeding in mice reveals thresholds in embryonic corpus callosum development.

Wahlsten D, Bishop KM, Ozaki HS.

Genes Brain Behav. 2006 Mar;5(2):170-88.

26.

Emx1 and Emx2 cooperate to regulate cortical size, lamination, neuronal differentiation, development of cortical efferents, and thalamocortical pathfinding.

Bishop KM, Garel S, Nakagawa Y, Rubenstein JL, O'Leary DD.

J Comp Neurol. 2003 Mar 17;457(4):345-60.

PMID:
12561075
27.
28.

Regulation of area identity in the mammalian neocortex by Emx2 and Pax6.

Bishop KM, Goudreau G, O'Leary DD.

Science. 2000 Apr 14;288(5464):344-9.

29.
30.

Sex differences in the human corpus callosum: myth or reality?

Bishop KM, Wahlsten D.

Neurosci Biobehav Rev. 1997 Sep;21(5):581-601. Review.

PMID:
9353793
31.

Evaluation of ambient asbestos concentrations in buildings following the Loma Prieta earthquake.

van Orden DR, Lee RJ, Bishop KM, Kahane D, Morse R.

Regul Toxicol Pharmacol. 1995 Feb;21(1):117-22.

PMID:
7784624

Supplemental Content

Loading ...
Support Center